Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Down 1.3% – Here’s What Happened

Unicycive Therapeutics, Inc. (NASDAQ:UNCY)’s stock price traded down 1.3% on Friday. The stock traded as low as $3.71 and last traded at $3.89. Approximately 1,212,401 shares traded hands during mid-day trading, an increase of 15% from the average session volume of 1,055,401 shares. The stock had previously closed at $3.94.

Key Headlines Impacting Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: The FDA accepted Unicycive’s resubmitted New Drug Application for oxylanthanum carbonate, a potential phosphate binder for patients with chronic kidney disease on dialysis. The resubmission includes Chemistry, Manufacturing, and Controls data from a new drug-product manufacturing vendor. The FDA assigned a March 25, 2027 PDUFA action date, providing a defined regulatory catalyst, although acceptance does not guarantee approval. FDA acceptance and PDUFA date article
• Positive Sentiment: The average analyst price target reportedly increased 12.32% to $32.54, suggesting substantial potential upside relative to recent trading levels. However, price targets can change quickly and may reflect limited analyst coverage for the clinical-stage biotechnology company. Analyst price target article
• Neutral Sentiment: Multiple law firms reminded investors of a November 2, 2026 lead-plaintiff deadline in a pending securities class action covering purchases from December 29, 2025 through June 29, 2026. The notices largely repeat the same litigation information rather than represent new operating developments. Class-action deadline notice
• Negative Sentiment: The lawsuit alleges Unicycive failed to disclose that it had not inspected or audited its third-party manufacturer’s facility for current Good Manufacturing Practice compliance before an earlier NDA resubmission. Plaintiffs claim this exposed investors to another Complete Response Letter and contributed to a reported 39.1% stock decline. The allegations have not been proven, but the litigation creates legal costs, reputational risk, and uncertainty around the company’s manufacturing readiness. Securities lawsuit allegations

Analysts Set New Price Targets

A number of research analysts have issued reports on UNCY shares. Guggenheim reissued a “buy” rating and issued a $25.00 price target (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, September 4th. Zacks Research upgraded shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. HC Wainwright cut their price target on Unicycive Therapeutics from $15.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, September 29th. Finally, Benchmark reaffirmed a “speculative buy” rating and set a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 20th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $18.25.

Unicycive Therapeutics Trading Down 1.3%

The company has a market cap of $108.34 million, a price-to-earnings ratio of -2.22 and a beta of 1.83. The firm’s fifty day simple moving average is $4.72 and its 200 day simple moving average is $5.96.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.41. As a group, sell-side analysts expect that Unicycive Therapeutics, Inc. will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of large investors have recently bought and sold shares of UNCY. Dimensional Fund Advisors LP purchased a new position in Unicycive Therapeutics during the first quarter worth about $940,000. Seven Fleet Capital Management LP boosted its position in Unicycive Therapeutics by 85.6% during the second quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock worth $521,000 after purchasing an additional 47,700 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Unicycive Therapeutics in the 2nd quarter worth about $248,000. Bank of America Corp DE lifted its holdings in shares of Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after purchasing an additional 29,378 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in Unicycive Therapeutics during the 1st quarter valued at $161,000. Hedge funds and other institutional investors own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease. The company’s primary focus is hyperphosphatemia, a condition in which phosphate levels become abnormally high in patients with chronic kidney disease, particularly those receiving dialysis.

Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.